z-logo
open-access-imgOpen Access
Utility of neoadjuvant therapy in rectal GIST
Author(s) -
Víctor LópezLópez,
Juan Ángel Fernández,
Pascual Parrilla
Publication year - 2017
Publication title -
revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2017.4751/2016
Subject(s) - medicine , gist , neoadjuvant therapy , resection , imatinib , surgical resection , surgery , general surgery , cancer , stromal cell , breast cancer , myeloid leukemia
Neoadjuvant therapy with Imatinib is the preferred treatment for rectal GISTs in order to reduce the aggressiveness of a surgical resection. At present, surgical resection does not require wide surgical margins. There is also a lot of controversy with regard to the need for a broad anatomical resection or if a local resection is sufficient and maintains maximum oncological safety and minimum morbidity and mortality. We present a case report of a rectal GIST with a good response to neoadjuvant treatment which allowed a transanal resection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom